BIIB vs GILD Stock Comparison: AI Score, Valuation, Performance and Upside
Both BIIB and GILD are large-cap biotechs with established specialty drug franchises facing varying degrees of competitive pressure and working to build next-generation growth drivers. Gilead has a more durable, highly cash-generative HIV franchise, while Biogen is navigating a more complex MS decline and Alzheimer's commercial uncertainty.
BIIB vs GILD compares two established large-cap biotechs — Biogen's neurology-focused franchise navigating MS decline and Alzheimer's opportunity, versus Gilead's stable HIV cash engine expanding into oncology.
BIIB holds the edge across 3 of 5 key metrics in this comparison. BIIB leads on both 1-year return (+49.85%) and forward P/E quality (13.21x vs 14.73x for GILD), a relatively favorable combination of momentum and valuation. GILD leads on both revenue growth (10.20%) and operating margin (33.68%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies similar upside for both: +8.11% for BIIB and +8.05% for GILD.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- See potential value in Biogen's Alzheimer's franchise if Leqembi adoption accelerates
- Believe the multiple sclerosis franchise provides adequate near-term cash generation
- Are comfortable with higher execution uncertainty in exchange for Alzheimer's disease upside potential
- Want exposure to a stable, large-cap biotech with a durable HIV cash cow
- Value Gilead's expanding oncology portfolio in breast cancer and CAR-T
- Prefer a more predictable, income-generating biotech with a meaningful dividend
| Metric | BIIB | GILD |
|---|---|---|
| AI scorei | 29.0 | 42.9 |
| AI ranki | #2343 | #899 |
| Latest closei | $215.50 | $150.11 |
| 1M returni | -2.74% | +1.70% |
| 6M returni | +17.50% | +6.38% |
| 1Y returni | +49.85% | +32.12% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | BIIB | GILD |
|---|---|---|
| 1Y ago | $14.99K (+49.9%) started 2025-09-18 | $13.21K (+32.1%) started 2025-09-18 |
| 5Y ago | $7.22K (-27.8%) started 2021-09-20 | $28.21K (+182.1%) started 2021-09-20 |
| 10Y ago | $7.1K (-29.0%) started 2016-09-19 | $37.67K (+276.7%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | BIIB | GILD |
|---|---|---|
| Market capi | $32.28B | $180.64B |
| Trailing P/Ei | 38.74 | 17.74 |
| Forward P/Ei | 13.21 | 14.73 |
| Price/Salesi | 1.99 | 4.87 |
| EV/Revenuei | 3.92 | 6.63 |
| Analyst targeti | $236.22 | $157.41 |
| Target upsidei | +8.11% | +8.05% |
| Metric | BIIB | GILD |
|---|---|---|
| Revenue growthi | 3.40% | 10.20% |
| Earnings growthi | -84.80% | 54.80% |
| EPS growthi | -84.80% | +54.80% |
| FCF margini | +12.63% | +32.07% |
| Operating margini | 25.06% | 33.68% |
| Profit margini | 8.32% | -10.64% |
| ROIC proxyi | 4.58% | -20.68% |
| Return on equityi | 4.58% | -20.68% |
| Dividend yieldi | N/A | 2.20% |
| Payout ratioi | 0.00% | 43.40% |
| Dividend growth streaki | N/A | No increase yet |
| Betai | 0.16 | 0.34 |
| Debt/equityi | 44.33 | 223.47 |
| Current ratioi | 1.86 | 1.26 |
| Quick ratioi | 0.94 | 0.90 |
Over the past year, BIIB and GILD have moved weakly in the same direction (correlation of 0.34), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | BIIB | GILD |
|---|---|---|---|
| 1Y | Growthi | +49.85% | +32.12% |
| CAGRi | +49.89% | +32.14% | |
| Volatilityi | 35.01% | 26.54% | |
| Sharpe ratioi | 1.21 | 1.02 | |
| Sortino ratioi | 1.91 | 1.61 | |
| Max drawdowni | 14.34% | 22.03% | |
| Current drawdowni | 4.01% | 3.65% | |
| Avg drawdowni | 4.87% | 8.03% | |
| Ulcer Indexi | 5.87% | 10.23% | |
| Max daily dropi | 8.17% | 3.72% | |
| Max wkly dropi | 12.37% | 5.98% | |
| 5Y | Growthi | -27.80% | +143.25% |
| CAGRi | -6.31% | +19.48% | |
| Volatilityi | 34.65% | 24.79% | |
| Sharpe ratioi | -0.16 | 0.66 | |
| Sortino ratioi | -0.25 | 1.02 | |
| Max drawdowni | 64.35% | 26.59% | |
| Current drawdowni | 32.25% | 3.65% | |
| Avg drawdowni | 31.70% | 9.00% | |
| Ulcer Indexi | 35.89% | 10.96% | |
| Max daily dropi | 8.17% | 10.15% | |
| Max wkly dropi | 13.62% | 9.78% | |
| 10Y | Growthi | -29.00% | +160.48% |
| CAGRi | -3.37% | +10.05% | |
| Volatilityi | 41.37% | 25.59% | |
| Sharpe ratioi | 0.01 | 0.33 | |
| Sortino ratioi | 0.01 | 0.49 | |
| Max drawdowni | 72.66% | 30.47% | |
| Current drawdowni | 48.04% | 3.65% | |
| Avg drawdowni | 34.71% | 13.26% | |
| Ulcer Indexi | 39.18% | 15.16% | |
| Max daily dropi | 29.23% | 10.15% | |
| Max wkly dropi | 34.30% | 12.29% |
| Category | BIIB | GILD |
|---|---|---|
| Company | Biogen Inc. | Gilead Sciences, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | Biogen is a large-cap biotechnology company focused on neurological diseases, including its established multiple sclerosis franchise (Tecfidera, Tysabri, Avonex) and its controversial Alzheimer's disease drugs (Aduhelm, Leqembi) developed in partnership with Eisai. | Gilead Sciences is a large-cap biotechnology company known for its dominant HIV antiretroviral franchise (Biktarvy, Descovy) and oncology portfolio (Trodelvy, Yescarta), with ongoing efforts to expand in viral hepatitis, inflammation, and other areas. |
| Investor focus | Investors track Leqembi adoption for Alzheimer's disease, Biogen's multiple sclerosis franchise durability against biosimilar and competitive pressure, and the overall pipeline strategy to offset declining MS revenues. | Investors track Biktarvy's HIV market leadership, Trodelvy's expansion in breast cancer and beyond, Yescarta's performance in CAR-T therapy, and Gilead's business development pipeline to supplement internal R&D. |
- Established leader in multiple sclerosis with a broad portfolio of FDA-approved therapies
- Leqembi (lecanemab) represents a potential franchise in Alzheimer's if it achieves meaningful commercial adoption
- Strong balance sheet and free cash flow provides flexibility for acquisitions and pipeline investment
- Biktarvy is the leading HIV treatment with a large, stable, recurring revenue base from patients on long-term therapy
- Oncology portfolio through Trodelvy (breast cancer) and Yescarta (CAR-T) provides diversification beyond HIV
- Strong cash flow from HIV franchise funds acquisitions and pipeline investment
- MS franchise faces biosimilar competition and revenue pressure as key drugs lose exclusivity
- Leqembi has seen slow initial commercial adoption due to complex administration, safety monitoring, and payer access issues
- Biogen has had a difficult period of strategic uncertainty following the controversial and then withdrawn Aduhelm Alzheimer's drug
- HIV franchise, while durable, faces eventual long-acting injectable competition and generics over time
- Oncology products Trodelvy and Yescarta are growing but still represent a smaller share of revenue than HIV
- Gilead has a mixed recent track record with its acquisitions relative to the prices paid
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.